EUFLEXXA(R) superior to IA saline for pain relief in knee OA
Ferring Pharmaceuticals Inc. has presented results from the FLEXX Trial of Osteoarthritis (OA) of the Knee at the Osteoarthritis Research Society International 2008 World Congress in Rome, Italy. The results show that EUFLEXXA(R), a highly pure non-avian high molecular weight form of intra-articular hyaluronic acid, is superior to intra-articular saline for pain relief in knee OA at the end of six months. The double-blind study had enrolled 586 patients. EUFLEXXA is the first hyaluronic acid derived from non-avian that has been approved in the U.S. for knee OA pain.

A meta-analysis carried out by Carsten Moser of the Grönemeyer Institute for Microtherapy and Peter Wehling of the Molecular Medicine Foundation has found out that most of the therapies for knee osteoarthritis (OA) are ineffective, some of them being even risky. Another finding was that often, prescribed anti-rheumatic drugs do no good and have side effects. Not even a single standard treatment was found for the disorder. The researchers emphasize the need for a plan that focuses on individual treatment based on a comprehensive diagnosis of symptoms of each patient.
Researchers at the University of Texas have developed a polymer-based delivery system which could lead to vaccines that would be more effective and specific to the infectious disease. The engineers have used ribonucleic acid (RNA) molecules for the purpose. The two year long study used the new system on mice, delivering a DNA-based hepatitis B vaccine. The immune response was found to be much stronger as compared to the conventional system.
SensiGen LLC has made an announcement about a new program to make the company’s AttoSense™ HPV assay available to head and neck cancer researchers worldwide. The declaration has followed the announcement of results of recent studies conducted at the University of Michigan. These conclude that the success of various treatment options is determined by the viral load of HPV in tissue samples from patients. With the AttoSense™ HPV test, selecting the most effective therapy for a particular patient will be easier. The diagnostic assay can accurately identify minute quantities of the biomarkers that indicate the beginning of major diseases or their causing pathogens.
A research conducted by the University of Texas Medical School has discovered some antibodies that have the potential to prevent an HIV-positive person from progressing to AIDS. This study could be used to develop a vaccine or microbicides to prevent people who are not infected with HIV from getting in contact with it. Catalytic antibodies attack on HIV’s outer shell where the virus binds to immune system cells, preventing the entry of virus into the cells. According to the researchers, the antibodies are present in lupus patients whose immune systems, generally, malfunction and produce a number of unusual antibodies.
A research conducted at
A research conducted by the University of Western Ontario and
A research at the School of Naturopathic Medicine at
One-fifth of Ayurvedic medicines made in the United States and India ordered from 25 websites by a team from Boston University School of Medicine and
New tests of